PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment 2015-2024 - Research and Markets

Research and Markets (http://www.researchandmarkets.com/research/hc7wft/pharmapoint_dry) has announced the addition of the "PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024" report to their offering.

Dry Eye Syndrome (DES), also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocular surface. The DES market has had few new therapeutics in the last decade with Japan seeing the most change in this time with the arrival of Diquas and Mucosta in 2010 and 2013, respectively.

However, the lack of treatment options is about to change with the expected launch of numerous pipeline DES drugs during the forecast period, which will be a significant driver of growth in the 9MM. Indeed, this change has already been initiated with Ikervis' recent arrival in Europe in 2015. Furthermore, additional marketing approvals are being sought for currently marketed DES drugs, Restasis and Diquas, in new countries in the 9MM, which will provide a source of growth in this market.

Key Questions Answered

- The DES market has been dominated by artificial tears therapy and by Restasis (in the US) for many years, with little approved therapeutic options available in the 9MM. New classes of drugs are anticipated to reach the market within the forecast period. How will these change the market overall during the forecast period? Will Restasis maintain market dominance in 2024?

- The current late stage DES pipeline is varied, with first-in-class drugs in development with innovative modes of action. Which of these will have the biggest impact on the market? What strategies are developers undertaking to penetrate this chronically underserved market? Will these fulfill any unmet needs?

- Population aging is occurring in almost all countries worldwide, particularly in the 9MM. This is expected to have a significant impact on the prevalence of age-related diseases such as DES. How will epidemiological changes impact the growth of the future market?

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Epidemiology

5 Disease Management

6 Competitive Assessment

7 Unmet Need and Opportunity

8 Pipeline Assessment

9 Current and Future Players

10 Market Outlook

11 Appendix

Companies Mentioned

• Alcon
• Allergan
• Herantis
• Mimetogen
• Mitotech
• Otsuka
• RegeneRx
• Santen
• Shire
  

For more information visit http://www.researchandmarkets.com/research/hc7wft/pharmapoint_dry

View source version on businesswire.com: http://www.businesswire.com/news/home/20160212005270/en/